Stocks
Citi Maintains Hold on Amgen Amid Analyst's Impressive Track Record
Citi analyst Geoff Meacham has maintained his hold rating for Amgen (AMGN.US) and kept its target price at $405. This decision comes after reviewing the company's performance. According to TipRanks data, Meacham has a success rate of 58.3% and an average return of 15.7% over the past year.
This rating is based on his past recommendations, which have been tracked by TipRanks. The analyst's ratings are used to create virtual portfolios that are adjusted according to changes in the market.